- Home
- WU vs ADPT Comparison
WU vs ADPT Comparison
Compare WU & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | ADPT |
|---|---|---|
| Founded | 1851 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WU | ADPT |
|---|---|---|
| Price | $7.22 | $17.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $9.00 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 7.5M | 3.0M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $4,050,700,000.00 | $276,976,000.00 |
| Revenue This Year | $8.50 | $3.98 |
| Revenue Next Year | $4.73 | $22.72 |
| P/E Ratio | $35.73 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $7.11 | $9.96 |
| 52 Week High | $10.35 | $20.76 |
Technical Indicators
Market Signals| Indicator | WU | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 59.38 |
| Support Level | N/A | $14.87 |
| Resistance Level | $9.78 | $17.72 |
| Average True Range (ATR) | 0.22 | 1.37 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.64 | 58.31 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.